1). Targeting CRLs for the treatment of ovarian cancer
2). Color-Screens to identify lineage specific multi-drug combinations
3). ReFLEX combinations to target drug induced vulnerabilities
Assistant Professor of Research in Systems and Computational Biomedicine
The lab works to develop and deploy precision-medicine workflows to compare alternative therapeutic regimens and to identify effective therapeutic strategies for individual patients, as well as the best patient population for emerging therapeutics.
My lab's research program focuses on the use of patient-derived tumor organoid models to study the effects of small molecule inhibitors and genetic perturbations upon therapeutic responses in cancer. To accomplish this goal, over the last ten years we have worked to develop functional genomics/precision oncology pipelines that integrate multi-omics with functional modeling in order to identify and understand tumor specific drug sensitivities. The lab, which resides within the Englander Institute for Precision Medicine, is comprised of a multidisciplinary team that has developed workflows to study patient-derived immune-organoid co-culture models in order to compare alternative therapeutic regimens, and to identify effective therapeutic strategies for individual patients, as well as the best patient population for emerging therapeutics.
As a team we have come to focus on developing alternative therapeutics for ovarian cancer, leveraging kinase activity, drug sensitivity testing, and genomics to identify and combine agents to improve treatment options for this devastating disease.
Figure 1.
Figure 2.
Biography
I am the Director of the Organoid Platform of the Englander Institute for Precision Medicine and an Assistant Professor in the Department of Systems and Computational Biomedicine at Weill Cornell Medicine. The overarching goal of my research program is to use functional modeling techniques to identify and elucidate the molecular mechanisms that underpin tumor specific drug sensitivities so that they can be exploited in the clinic. Specifically, my labs research program focuses on the use of patient derived tumor organoid models to study the effects of small molecule inhibitors and genetic perturbations upon therapeutic responses in cancer.
Distinctions:
Director, Organoid Platform, Englander Institute for Precision Medicine
Scientists Choice Award, Drug Discovery & Development, Editorial of the year 2023
Claridge, S. E., Nath, S., Baum, A., Farias, R., Cavallo, J. A., Rizvi, N. M., De Boni, L., Park, E., Granados, G. L., Hauesgen, M., Fernandez-Rodriguez, R., Kozan, E. N., Kanshin, E., Huynh, K. Q., Chen, P. J., Wu, K., Ueberheide, B., Mosquera, J. M., Hirsch, F. R., DeVita, R. J., … Hopkins, B. D. (2025). Functional genomics pipeline identifies CRL4 inhibition for the treatment of ovarian cancer.Clinical and translational medicine, 15(2), e70078.
Pauli, C., Hopkins, B. D., Prandi, D., Shaw, R., Fedrizzi, T., Sboner, A., Sailer, V., Augello, M., Puca, L., Rosati, R., McNary, T. J., Churakova, Y., Cheung, C., Triscott, J., Pisapia, D., Rao, R., Mosquera, J. M., Robinson, B., Faltas, B. M., Emerling, B. E., … Rubin, M. A. (2017). Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine.Cancer discovery, 7(5), 462–477.
